دورية أكاديمية
Microengineered In Vitro Assays for Screening and Sorting Manufactured Therapeutic T Cells.
| العنوان: | Microengineered In Vitro Assays for Screening and Sorting Manufactured Therapeutic T Cells. |
|---|---|
| المؤلفون: | Muhuri AK; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA.; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA., Alapan Y; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA.; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA., Camargo CP; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA.; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA., Thomas SN; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA.; Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA.; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA.; Winship Cancer Institute, Emory University, Atlanta, GA. |
| المصدر: | Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2024 Jan 15; Vol. 212 (2), pp. 199-207. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association of Immunologists Country of Publication: United States NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Bethesda, MD : American Association of Immunologists Original Publication: Baltimore : Williams & Wilkins, c1950- |
| مواضيع طبية MeSH: | Neoplasms*/therapy , T-Lymphocytes*, Humans ; Cell Movement ; Genetic Engineering ; Immunotherapy |
| مستخلص: | Adoptively transferred T cells constitute a major class of current and emergent cellular immunotherapies for the treatment of disease, including but not limited to cancer. Although key advancements in molecular recognition, genetic engineering, and manufacturing have dramatically enhanced their translational potential, therapeutic potency remains limited by poor homing and infiltration of transferred cells within target host tissues. In vitro microengineered homing assays with precise control over micromechanical and biological cues can address these shortcomings by enabling interrogation, screening, sorting, and optimization of therapeutic T cells based on their homing capacity. In this article, the working principles, application, and integration of microengineered homing assays for the mechanistic study of biophysical and biomolecular cues relevant to homing of therapeutic T cells are reviewed. The potential for these platforms to enable scalable enrichment and screening of next-generation manufactured T cell therapies for cancer is also discussed. (Copyright © 2024 by The American Association of Immunologists, Inc.) |
| References: | Hum Gene Ther. 2002 Nov 1;13(16):1971-80. (PMID: 12427307) J Immunol. 2011 Sep 1;187(5):2356-64. (PMID: 21795598) Cancer Discov. 2014 May;4(5):522-6. (PMID: 24795012) J Cell Sci. 2015 Oct 15;128(20):3731-43. (PMID: 26349809) Eur J Immunol. 1995 Apr;25(4):1025-31. (PMID: 7537667) J Natl Cancer Inst. 2007 Aug 1;99(15):1188-99. (PMID: 17652277) JCI Insight. 2017 Jun 15;2(12):. (PMID: 28614795) J Lab Autom. 2015 Apr;20(2):107-26. (PMID: 25586998) Nat Immunol. 2001 Jun;2(6):515-22. (PMID: 11376338) Clin Transl Med. 2021 Feb;11(2):e280. (PMID: 33634970) J Exp Med. 2001 Oct 1;194(7):953-66. (PMID: 11581317) Methods Mol Biol. 2005;294:15-22. (PMID: 15576901) J Clin Med. 2022 Oct 24;11(21):. (PMID: 36362494) Immunotherapy. 2011 Oct;3(10):1223-33. (PMID: 21995573) Microfluid Nanofluidics. 2009;7(6):739. (PMID: 32214956) Assay Drug Dev Technol. 2022 Feb-Mar;20(2):75-82. (PMID: 35196113) Br J Cancer. 2002 Oct 21;87(9):1034-41. (PMID: 12434297) Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2705-11. (PMID: 15331369) Microvasc Res. 2011 Nov;82(3):210-20. (PMID: 21763328) Semin Oncol. 2012 Apr;39(2):215-26. (PMID: 22484193) Cell Rep. 2023 Mar 28;42(3):112175. (PMID: 36848287) Blood. 2007 Feb 15;109(4):1381-6. (PMID: 17038526) J Immunol Methods. 1994 Apr 15;170(2):159-66. (PMID: 8157994) Blood Cancer Discov. 2021 Sep;2(5):408-422. (PMID: 34568831) Cell Rep. 2015 Mar 3;10(8):1261-1268. (PMID: 25732817) Int J Mol Sci. 2015 Aug 05;16(8):18149-84. (PMID: 26251901) J Immunol. 2012 Feb 1;188(3):1421-30. (PMID: 22219321) Signal Transduct Target Ther. 2022 Aug 6;7(1):272. (PMID: 35933430) Integr Biol (Camb). 2017 Apr 18;9(4):313-327. (PMID: 28262902) Sci Rep. 2021 May 13;11(1):10310. (PMID: 33986379) Sci Rep. 2016 May 06;6:25557. (PMID: 27150137) Pharmaceutics. 2011 Mar 11;3(1):107-24. (PMID: 24310428) Lab Chip. 2021 Jun 1;21(11):2142-2152. (PMID: 33913456) J Clin Invest. 1998 Oct 15;102(8):1526-33. (PMID: 9788965) Clin Cancer Res. 2011 Jul 15;17(14):4719-30. (PMID: 21610146) J Cell Biol. 1997 Feb 10;136(3):717-27. (PMID: 9024700) Clin Cancer Res. 2011 Aug 15;17(16):5343-52. (PMID: 21737507) J Cell Biol. 1994 Dec;127(5):1485-95. (PMID: 7525609) Blood. 2016 Sep 1;128(9):1270-81. (PMID: 27443292) Cancer J. 2012 Mar-Apr;18(2):160-75. (PMID: 22453018) Mol Ther Methods Clin Dev. 2019 Nov 29;16:136-144. (PMID: 31988978) J Immunother Cancer. 2019 Mar 12;7(1):68. (PMID: 30867051) Elife. 2020 Jun 08;9:. (PMID: 32510333) Nat Immunol. 2005 Dec;6(12):1182-90. (PMID: 16369557) J Immunol. 2001 Nov 1;167(9):4791-5. (PMID: 11673480) Elife. 2020 Oct 13;9:. (PMID: 33046212) Sci Rep. 2016 Nov 07;6:36440. (PMID: 27819270) Lab Chip. 2021 Apr 20;21(8):1527-1539. (PMID: 33616124) J Clin Invest. 2015 Mar 2;125(3):1019-32. (PMID: 25621495) Lab Invest. 2017 Jun;97(6):669-697. (PMID: 28346400) Methods Enzymol. 2008;443:155-76. (PMID: 18772016) J Biol Chem. 2019 Nov 29;294(48):18465-18474. (PMID: 31628196) Cancer Immunol Immunother. 2008 Feb;57(2):271-80. (PMID: 17646988) Clin Hemorheol Microcirc. 2008;39(1-4):303-10. (PMID: 18503139) Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532) Nature. 1996 Jan 18;379(6562):266-9. (PMID: 8538793) Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):258-63. (PMID: 9419363) Ir J Med Sci. 2021 Feb;190(1):41-57. (PMID: 32607912) Brain. 2002 Jun;125(Pt 6):1297-308. (PMID: 12023318) Nat Immunol. 2011 Dec 04;13(1):67-76. (PMID: 22138716) Blood. 2009 Jun 18;113(25):6392-402. (PMID: 19377047) Adv Cancer Res. 2015;128:263-307. (PMID: 26216636) Int J Mol Sci. 2021 Jul 30;22(15):. (PMID: 34361000) Eur J Immunol. 1995 Dec;25(12):3482-8. (PMID: 8566041) J Immunol. 2000 May 15;164(10):5035-40. (PMID: 10799858) J Vis Exp. 2020 Jun 23;(160):. (PMID: 32658183) Adv Healthc Mater. 2019 Mar;8(5):e1900001. (PMID: 30734529) Soft Matter. 2014 May 7;10(17):2961-70. (PMID: 24695813) J Leukoc Biol. 2009 Dec;86(6):1285-94. (PMID: 19797295) Bioorg Chem. 2019 Nov;92:103250. (PMID: 31580982) PLoS One. 2013 Sep 19;8(9):e75151. (PMID: 24069389) Adv Biosyst. 2019 Mar;3(3):e1800328. (PMID: 32627398) |
| معلومات مُعتمدة: | U01 CA214354 United States CA NCI NIH HHS; R01 CA207619 United States CA NCI NIH HHS; R01 CA247484 United States CA NCI NIH HHS |
| تواريخ الأحداث: | Date Created: 20240102 Date Completed: 20240117 Latest Revision: 20240213 |
| رمز التحديث: | 20240213 |
| مُعرف محوري في PubMed: | PMC10783858 |
| DOI: | 10.4049/jimmunol.2300488 |
| PMID: | 38166247 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1550-6606 |
|---|---|
| DOI: | 10.4049/jimmunol.2300488 |